Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of Probasin-RAS transgenic mice

Prostate

Volumn 59, Issue 4, 2004, Pages 448-459

  Scherl, Alexis ^a   Li, Jiu Feng ^a   Cardiff, Robert D ^b   Schreiber Agus, Nicole ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Ullmann 809 ^*  (United States)

Author keywords

Itf tff3; Mouse model; PIN; Prostate cancer; Transdifferentiation

Indexed keywords

PEPTIDE DERIVATIVE; PROBASIN; PROTEIN TFF3; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GOBLET CELL; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MALE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANDROGEN-BINDING PROTEIN; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DIGESTIVE SYSTEM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; MICE; MICE, TRANSGENIC; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 2442653901     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20020     Document Type: Article

References (73)

1. http://www.cancer.org
2. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet 2003;361(9362):1045-1053.
3. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;2(2):113-116.
4. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361): 955-964.
5. Nicholson B, Theodorescu D. Molecular therapeutics in prostate cancer. Histol Histopathol 2003;18(1):275-298.
6. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
7. Sharma P, Schreiber-Agus N. Mouse models of prostate cancer. Oncogene 1999;18(38):5349-5355.
8. Castrillon DH, DePinho RA. Modeling prostate cancer in the mouse. Adv Cancer Res 2001;82:187-204.
9. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: Past, present, and future. Semin Cancer Biol 2001;11(3):245-260.
10. Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet 2002;18(5)-S1-S5.
11. Powell WC, Cardiff RD, Cohen MB, Miller GJ, Roy-Burman P. Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. Curr Drug Targets 2003;4(3):263-279.
12. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56(6):917-930.
13. Thompson TC, Timme TL, Park SH, Yang G, Ren C. Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 2000;43(4):248-254.
14. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
15. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56(18):4096-4102.
16. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8(2):230-239.
17. Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 2000;43(4): 278-285.
18. Zhang X, Chen MW, Ng A, Ng PY, Lee C, Rubin M, Olsson CA, Buttyan R. Abnormal prostate development in C3(1)-bcl-2 transgenic mice. Prostate 1997;32(1):16-26.
19. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000;97(7): 3455-3460.
20. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM. Roles for nkx3.1 in prostate development and cancer [in process citation]. Genes Dev 1999;13(8):966-977.
21. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002;22(5):1495-1503.
22. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19(4):348-355.
23. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96(4):1563-1568.
24. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller GJ. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997;30(1):53-57.
25. Shiraishi T, Muneyuki T, Fukutome K, Ito H, Kotake T, Watanabe M, Yatani R. Mutations of ras genes are relatively frequent in Japanese prostate cancers: Pointing to genetic differences between populations. Anticancer Res 1998;18(4B): 2789-2792.
26. Suzuki H, Aida S, Akimoto S, Igarashi T, Yatani R, Shimazaki J. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res 1994;85(8): 847-852.
27. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992; 52(21):5991-5996.
28. Shibata MA, Ward JM, Devor DE, Liu ML, Green JE. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations. Cancer Res 1996;56(21): 4894-4903.
29. Condon MS, Kaplan LA, Crivello JF, Horton L, Bosland MC. Multiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated with N-methyl-N-nitrosourea and testosterone. Mol Carcinog 1999;25(3):179-186.
30. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS, Jay G. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Kiras. Proc Natl Acad Sci USA 1994;91(25):11874-11878.
31. Lehr JE, Pienta KJ, Yamazaki K, Pilat MJ. A model to study c-myc and v-H-ras induced prostate cancer progression in the Copenhagen rat. Cell Mol Biol (Noisy-le-grand) 1998;44(6): 949-959.
32. Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, Greenberg NM, Kreisberg JI. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 1999;18(28):4120-4130.
33. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63(8):1981-1989.
34. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412(6849):822-826.
35. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62(15):4427-4433.
36. Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III, Emmert-Buck MR. Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33(1):9-15.
37. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr., Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61(16):5974-5978.
38. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res 2001;61(12):4683-4688.
39. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M, Grone HJ. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: A gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160(6):2169-2180.
40. Efrat S, Fleischer N, Hanahan D. Diabetes induced in male transgenic mice by expression of human H-ras oncoprotein in pancreatic beta cells. Mol Cell Biol 1990;10(4):1779-1783.
41. Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem 1980;107(2):303-314.
42. Sweetser DA, Kapur RP, Froelick GJ, Kafer KE, Palmiter RD. Oncogenesis and altered differentiation induced by activated Ras in neuroblasts of transgenic mice. Oncogene 1997;15(23): 2783-2794.
43. Park JH, Walls JE, Galvez JJ, Kim M, Abate-Shen C, Shen MM, Cardiff RD. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002;161(2):727-735.
44. Hansson GC, Baeckstrom D, Carlstedt I, Klinga-Levan K. Molecular cloning of a cDNA coding for a region of an apoprotein from the 'insoluble' mucin complex of rat small intestine. Biochem Biophys Res Commun 1994;198(1):181-190.
45. Manual of histologic staining methods of the Armed Forces Institute of Pathology. In: Luna LG, editor. New York: Blakiston Division, McGraw-Hill; 1968.
46. Taupin DR, Pang KC, Green SP, Giraud AS. The trefoil peptides spasmolytic polypeptide and intestinal trefoil factor are major secretory products of the rat gut. Peptides 1995; 16(6):1001-1005.
47. Price D. Comparative aspects of development and structure in the prostate. In: Kauffmann EVaG, editor. Biology of the prostate and related tissues. Washington, D.C: US Government Printing Office; 1963. pp 1-28.
48. Malumbres M BM. Timeline: RAS oncogenes: The first 30 years. Nat Rev Cancer 2003;3(6):459-465.
49. Maini A, Archer C, Wang CY, Haas GP. Comparative pathology of benign prostatic hyperplasia and prostate cancer. In Vivo 1997;11(4):293-299.
50. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400(6743):468-472.
51. Ricciardelli C MK, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998;4(4):963-971.
52. Montironi R, Santinelli A, Mazzucchelli R. Prostatic intraepithelial neoplasia and prostate cancer. Panminerva Med 2002; 44(3):213-220.
53. Corfield AP, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract: New prospects for mucins in the pathology of gastrointestinal disease. Gut 2000;47(4):589-594.
54. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995;57:607-634.
55. Sands BE, Podolsky DK. The trefoil peptide family. Annu Rev Physiol 1996;58:253-273.
56. Cox AD, Der CJ. Ras family signaling: Therapeutic targeting. Cancer Biol Ther 2002;1(6):599-606.
57. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3(1):11-22.
58. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A. Ras family genes: An interesting link between cell cycle and cancer. J Cell Physiol 2002;192(2):125-130.
59. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003;28(2):145-153.
60. Barrios R, Lebovitz RM, Wiseman AL, Weisoly DL, Matusik RJ, DeMayo F, Lieberman MW. RasT24 driven by a probasin promoter induces prostatic hyperplasia in transgenic mice. Transgenics 1996;2:23-28.
61. Giaretti W, Rapallo A, Sciutto A, Macciocu B, Geido E, Hermsen MA, Postma C, Baak JP, Williams RA, Meijer GA. Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 2000;21(2):49-57.
62. Losi L, Roncucci L, di Gregorio C, de Leon MP, Benhattar J. K-ras and p53 mutations in human colorectal aberrant crypt foci. J Pathol 1996;178(3):259-263.
63. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995;131(7):796-800.
64. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol 2002;3(3):187-194.
65. Slack JM, Tosh D. Transdifferentiation and metaplasia-switching cell types. Curr Opin Genet Dev 2001;11(5):581-586.
66. Dutt K, Scott M, Sternberg PP, Linser PJ, Srinivasan A. Transdifferentiation of adult human pigment epithelium into retinal cells by transfection with an activated H-ras proto-oncogene. DNA Cell Biol 1993;12(8):667-673.
67. Bar-Sagi D, Feramisco JR. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 1985;42(3):841-848.
68. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD, Kaestner KH. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122(3):689-696.
69. Goldblum JR. The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 2002;6(1):67-73.
70. Leung WK, Sung JJ. Review article: Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002;16(7): 1209-1216.
71. Saito S, Iwaki H. Mucin-producing carcinoma of the prostate: Review of 88 cases. Urology 1999;54(1):141-144.
72. Saez C, Japon MA, Conde AF, Poveda MA, Luna-More S, Segura DI. Sialomucins are characteristically O-acylated in poorly differentiated and colloid prostatic adenocarcinomas. Mod Pathol 1998;11(12):1193-1197.
73. Taupin D, Pedersen J, Familari M, Cook G, Yeomans N, Giraud AS. Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest 2001;81(3):397-408.